The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Sep. 27, 2012
Applicants:

Dongguk University Industry-academic Cooperation Foundation, Seoul, KR;

Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;

Inventors:

Kyeong Lee, Seoul, KR;

Mi-Sun Won, Daejeon, KR;

Hwan-Mook Kim, Daejeon, KR;

Song-Kyu Park, Daejeon, KR;

Ki-Ho Lee, Seoul, KR;

Chang-Woo Lee, Chungcheongbuk-do, KR;

Bo-Kyung Kim, Seoul, KR;

Hyun-Seung Ban, Daejeon, KR;

Kyung-Sook Chung, Daejeon, KR;

Naik Ravi, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 295/185 (2006.01); C07C 235/20 (2006.01); C07C 235/22 (2006.01); C07D 295/073 (2006.01); C07D 241/04 (2006.01); C07C 231/02 (2006.01); C07D 295/108 (2006.01); C07D 295/182 (2006.01); C07D 307/52 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); C07C 231/02 (2013.01); C07C 235/20 (2013.01); C07C 235/22 (2013.01); C07D 241/04 (2013.01); C07D 295/073 (2013.01); C07D 295/108 (2013.01); C07D 295/182 (2013.01); C07D 295/185 (2013.01);
Abstract

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.


Find Patent Forward Citations

Loading…